Role of Transplant and MRD in Newly Diagnosed MM

Author(s):

Krina K. Patel, MD, MSc,Amrita Krishnan, MD

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma

EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 3.Advances in the Treatment of High-Risk MM

Now Viewing

EP: 4.Role of Transplant and MRD in Newly Diagnosed MM

EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM

EP: 6.Treatment of Multiple Myeloma at Early Relapse

EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse

EP: 8.Updates on BCMA-Targeting Bispecifics in MM

EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma

EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on determining which newly diagnosed multiple myeloma patients should proceed to autologous stem cell transplant (ASCT) vs an induction-maintenance approach without ASCT. For high-risk patients, ASCT remains standard, but for standard-risk patients who achieve minimal residual disease (MRD) negativity with quadruplet induction, omitting transplant with prolonged maintenance therapy is reasonable. However, attaining MRD negativity from induction alone may not be enough, and sustained MRD negativity over time is ideal. There is also concern about declining health and stem cell collection feasibility with increasing patient age.

While historically ASCT with high-dose melphalan was considered the best antimyeloma therapy, novel agents now appear equally if not more efficacious. Still, ASCT improves initial progression-free survival.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.